SARM
LGD-4033 (Ligandrol)
SaveOne of the most studied non-steroidal SARMs, originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics. Phase I/II human data is available.
Quick verdict
Demonstrated lean mass gains in short-term Phase I/II trials but with dose-dependent hormonal suppression. Not approved for clinical use.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
A 21-day Phase I trial in healthy men showed dose-dependent increases in lean body mass and decreases in body fat. Significant suppression of total testosterone and SHBG was observed. Viking Therapeutics has advanced VK5211 (ligandrol) in Phase II for hip-fracture recovery.
Benefits
- Phase I lean mass gains at doses as low as 1 mg/day
- Oral bioavailability with once-daily dosing
- Phase II trial in hip fracture recovery underway
Dosage notes
Phase I used 0.1–1 mg/day over 21 days. No approved dose.
Side effects
- Testosterone suppression
- HDL reduction
- Headache
- Fatigue
Who should be cautious
Causes dose-dependent testosterone suppression. Not approved for human use. WADA-banned substance.
What this page cannot tell you
Short trial durations make long-term safety and efficacy uncertain. Functional outcome data is limited.
Leaderboard scores
- Muscle55
- Recovery35
- Libido15
Write a review
Sign in to write a review.